BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17504870)

  • 1. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
    Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
    J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
    Beaulieu S; Kinahan P; Tseng J; Dunnwald LK; Schubert EK; Pham P; Lewellen B; Mankoff DA
    J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
    Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.
    Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Charlop A; Lawton TJ; Schubert EK; Tseng J; Livingston RB
    J Nucl Med; 2002 Apr; 43(4):500-9. PubMed ID: 11937594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
    Sugawara Y; Fisher SJ; Zasadny KR; Kison PV; Baker LH; Wahl RL
    J Clin Oncol; 1998 Jan; 16(1):173-80. PubMed ID: 9440740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results.
    Sugawara Y; Zasadny KR; Kison PV; Baker LH; Wahl RL
    J Nucl Med; 1999 Sep; 40(9):1456-62. PubMed ID: 10492365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
    Dunnwald LK; Doot RK; Specht JM; Gralow JR; Ellis GK; Livingston RB; Linden HM; Gadi VK; Kurland BF; Schubert EK; Muzi M; Mankoff DA
    Clin Cancer Res; 2011 Apr; 17(8):2400-9. PubMed ID: 21364034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies.
    Jacene HA; Ishimori T; Engles JM; Leboulleux S; Stearns V; Wahl RL
    J Nucl Med; 2006 Jun; 47(6):950-6. PubMed ID: 16741304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Standard uptake value of 18F-fluorine-2-deoxyglucose is correlated with the expression of estrogen receptor in duct carcinoma of breast].
    Wen GH; Feng YL; Deng HF; Yu FZ; Liu DJ; Yuan JW; He XH; Huang KM; Liu SS; Yang M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May; 39(3):448-50. PubMed ID: 18575338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
    Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
    Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Schubert EK; Tseng J; Lawton TJ; Linden HM; Livingston RB
    J Nucl Med; 2003 Nov; 44(11):1806-14. PubMed ID: 14602864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
    Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
    J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body
    Dias AH; Pedersen MF; Danielsen H; Munk OL; Gormsen LC
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):837-850. PubMed ID: 32894338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis.
    Quarles van Ufford HM; van Tinteren H; Stroobants SG; Riphagen II; Hoekstra OS
    J Nucl Med; 2010 Oct; 51(10):1507-16. PubMed ID: 20847179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
    Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
    J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
    Berriolo-Riedinger A; Touzery C; Riedinger JM; Toubeau M; Coudert B; Arnould L; Boichot C; Cochet A; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1915-24. PubMed ID: 17579854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test-Retest Variability in Lesion SUV and Lesion SUR in
    Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
    J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.